{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:51:56Z","timestamp":1753876316056,"version":"3.41.2"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p\/>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Clinical studies have indicated minor beneficial effects of the calcium sensitizer levosimendan on clinical outcomes in patients undergoing cardiac surgery. Here, the influence of levosimendan administered 24 h before cardiac arrest on myocardial function was examined in rat hearts perfused in a Langendorff model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Levosimendan (Levo group) or NaCl (control group) was administered to 53 rats via drinking water 24 h prior to mounting excised hearts on a Langendorff apparatus. Cardiac arrest with or without cardioplegia was induced in both groups; another set of hearts was perfused continuously. During 90-min reperfusion at 36\u00b0C, functional parameters were measured and normalized to baseline values. Troponin I was quantified in coronary sinus effluent, and the functionality of isolated cardiomyocytes was studied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Oral application of levosimendan showed therapeutic efficacy. Baseline values were similar in the Levo and NaCl groups except for coronary flow. After ischaemia and reperfusion, Levo hearts did not recover better than NaCl hearts {left ventricular derived pressure: 63 [standard deviation (SD): 36.2] vs 46 (SD: 41.8)% baseline; P = 0.386}, In hearts exposed to cardioplegia, functional recovery only slightly differed in the Levo and NaCl groups [left ventricular derived pressure: 69.96 (SD: 12.7) vs 51.89 (SD: 28.1)% baseline; P = 0.09]. Cell shortening of cardiomyocytes isolated from hearts exposed to ischaemia or perfusion was better in Levo groups [cell shortening: 7.65 (SD: 1.95) %; 7.8 (SD: 1.79)% vs 6.28 (SD: 1.67)%; 6.5 (SD: 1.87)%, P &amp;lt; 0.001]; this benefit was absent in cardioplegia-treated hearts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Levosimendan applied orally before ischaemia\/reperfusion improves functional recovery, but this effect is only moderate when cardioplegia is included. Differences between hearts exposed to cardioplegia or to global ischaemia may indicate why levosimendan-related beneficial effects do not directly translate into better clinical outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejcts\/ezac168","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T20:12:44Z","timestamp":1645733564000},"source":"Crossref","is-referenced-by-count":0,"title":["Oral application of levosimendan before ischaemia\/reperfusion with or without cardioplegic arrest in rats"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-510X","authenticated-orcid":false,"given":"Andreas","family":"Boening","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Justus-Liebig-University , Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Welk","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Justus-Liebig-University , Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Heep","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Justus-Liebig-University , Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Hemmerich","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Justus-Liebig-University , Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-7002","authenticated-orcid":false,"given":"Bernd","family":"Niemann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Justus-Liebig-University , Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-4919","authenticated-orcid":false,"given":"Klaus-Dieter","family":"Schl\u00fcter","sequence":"additional","affiliation":[{"name":"Institute of Physiology, Justus-Liebig-University , Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4139-3117","authenticated-orcid":false,"given":"Zulfugar T","family":"Taghiyev","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Justus-Liebig-University , Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"2022093019001176600_ezac168-B1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2015.10.240","article-title":"Calcium sensitizers: what have we learned over the last 25 years?","volume":"203","author":"Pollesello","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022093019001176600_ezac168-B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1399-6576.2010.02381.x","article-title":"Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference","volume":"55","author":"Landoni","year":"2011","journal-title":"Acta Anaesthesiol Scand"},{"key":"2022093019001176600_ezac168-B3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1053\/j.jvca.2013.03.027","article-title":"Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis","volume":"27","author":"Harrison","year":"2013","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2022093019001176600_ezac168-B4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2017.9973","article-title":"Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial","volume":"318","author":"Cholley","year":"2017","journal-title":"JAMA"},{"key":"2022093019001176600_ezac168-B5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","article-title":"Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","volume":"376","author":"Mehta","year":"2017","journal-title":"N Engl J Med"},{"key":"2022093019001176600_ezac168-B6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13019-016-0556-2","article-title":"Impact of prophylactic administration of levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery\u2014a retrospective analysis","volume":"11","author":"Grieshaber","year":"2016","journal-title":"J Cardiothorac Surg"},{"key":"2022093019001176600_ezac168-B7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e32832f0ce4","article-title":"Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats","volume":"27","author":"Louhelainen","year":"2009","journal-title":"J Hypertens"},{"key":"2022093019001176600_ezac168-B8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.exger.2018.02.003","article-title":"Buckberg's blood cardioplegia for protection of adult and senile myocardium in a rat in vitro model of acute myocardial infarction","volume":"104","author":"Boening","year":"2018","journal-title":"Exp Gerontol"},{"key":"2022093019001176600_ezac168-B9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00395-018-0696-8","article-title":"Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection","volume":"113","author":"B\u00f8tker","year":"2018","journal-title":"Basic Res Cardiol"},{"key":"2022093019001176600_ezac168-B10","first-page":"56634","article-title":"Isolation and cultivation of adult rat cardiomyocytes","volume":"128","author":"Nippert","year":"2017","journal-title":"J Vis Exp"},{"key":"2022093019001176600_ezac168-B11","doi-asserted-by":"crossref","DOI":"10.1177\/1179546818771908","article-title":"Citrulline improves early post-ischemic recovery or rat hearts in vitro by shifting arginine metabolism from polyamine to nitric oxide formation","volume":"12.","author":"Heidorn","year":"2018","journal-title":"Clin Med Insights Cardiol"},{"key":"2022093019001176600_ezac168-B12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5414\/CPP40465","article-title":"Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure","volume":"40","author":"Kivikko","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2022093019001176600_ezac168-B13","first-page":"505","article-title":"Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia\/reperfusion in the Langendorff-perfused guinea pig heart","volume":"290","author":"Du Toit","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"2022093019001176600_ezac168-B14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/FJC.0b013e3180986230","article-title":"The cardioprotective effects of levosimendan: preclinical and clinical evidence","volume":"50","author":"Pollesello","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022093019001176600_ezac168-B15","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","article-title":"Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure","volume":"36","author":"Nieminen","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2022093019001176600_ezac168-B16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"2022093019001176600_ezac168-B17","doi-asserted-by":"crossref","first-page":"29269","DOI":"10.3402\/ljm.v10.29269","article-title":"The effect of levosimendan on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats","volume":"10","author":"Kiraz","year":"2015","journal-title":"Libyan J Med"},{"key":"2022093019001176600_ezac168-B18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.fjc.0000137163.22359.17","article-title":"Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion","volume":"44","author":"Eriksson","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022093019001176600_ezac168-B19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s003950050146","article-title":"The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts","volume":"94","author":"Kristof","year":"1999","journal-title":"Basic Res Cardiol"},{"key":"2022093019001176600_ezac168-B20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijcard.2015.02.022","article-title":"Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion","volume":"184","author":"Toller","year":"2015","journal-title":"Int J Cardiol"},{"key":"2022093019001176600_ezac168-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000551","article-title":"Use of levosimendan in cardiac surgery: an update after the LEVO-CTS, CHEETAH, and LICORN trials in the light of clinical practice","volume":"71","author":"Guarracino","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022093019001176600_ezac168-B22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0038-1675398","article-title":"Influence of medication-induced preconditioning or remote ischemic preconditioning on the intrinsic vascular extracellular RNA\/ribonuclease system in cardioprotection","volume":"67","author":"Tolkmitt","year":"2019","journal-title":"Thorac Cardiovasc Surg"},{"key":"2022093019001176600_ezac168-B23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.RES.77.1.107","article-title":"Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart","volume":"77","author":"Edes","year":"1995","journal-title":"Circ Res"},{"key":"2022093019001176600_ezac168-B24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/bja\/ael082","article-title":"Preconditioning effects of levosimendan in coronary artery bypass grafting\u2013a pilot study","volume":"96","author":"Tritapepe","year":"2006","journal-title":"Br J Anaesth"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/62\/4\/ezac168\/46221598\/ezac168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/62\/4\/ezac168\/46221598\/ezac168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T19:59:34Z","timestamp":1664567974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezac168\/6548865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezac168","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"type":"print","value":"1010-7940"},{"type":"electronic","value":"1873-734X"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,3,15]]},"article-number":"ezac168"}}